MEMPHIS, TN / ACCESSWIRE / June 23, 2020 / ATWEC Technologies (OTC PINK:ATWT) a leader in the child safety industry is pleased to announce its new KV-4 child reminder system has been successfully installed in Child transport vehicles located at The Kids Child Center in West Memphis AR. This pilot program is one of two intended to act as evaluations of its operation and durability and will be evaluated over a 30-day period.

According to Alex Wiley, CEO of ATWEC Technologies, "The system is easily installed and its functionality and operation are flawless. Its durability and ease of use is very impressive and the client is very pleased with the results. The KV-4's new RFID tag operability is welcomed by the vehicle operators and the director of the center has already committed to ordering systems for its remaining child transport vehicles. This is an exciting time for the employees and distributors of the KV-4 unit as negotiations for a future pilot program in the country's largest school district are already in the planning process."

About ATWEC Technologies, Inc. (OTC PINK:ATWT):

ATWEC Technologies, Inc. is a child safety and security technology company, headquartered in Memphis, TN, in business since 1979. ATWT has developed three unique child safety devices which protect children while they are being transported, both to and from schools, events, and homes, and gives parents and administrators ‘peace of mind'. ATWT has been issued patent number 7,646,288, B2 for its KV-3 system by the US patent office, and its business model is associated with legislation designed to mandate these systems for school and other vehicles, on a state-by-state basis. The KV-3 and the Kiddie Alert™ backup systems are currently being sold to customers across the globe. The Company trades on the OTC Markets under the symbol "ATWT", and the Company's website is www.atwec.com.

NOTE: Certain statements made in this press release are forward looking statements within the scope of the Private Securities Act of 1995. Such statements involve known and unknown risks. Uncertainties and other mitigating factors may influence desired outcomes. Such risks, uncertainties and/or other mitigating factors include but are not limited to new economic conditions, risks associated in product development, market acceptance of new products and continuing product demand, level of competition and other factors both known and unknown as described within this Company's reports and other filings with appropriate regulatory agencies.

Contact:

ATWEC Technologies, Inc.
901-690-2471
901-289-2621

SOURCE: ATWEC Technologies, Inc.

ReleaseID: 594873

TORONTO, ONTARIO / ACCESSWIRE / June 23, 2020 / GlobeX Data Ltd. (OTCQB:SWISF)(CSE:SWIS) ("GlobeX" or the "Company"), the leader in Swiss hosted cyber security and Internet privacy solutions for secure data management and secure communications, is pleased to announce that it has received increased interest for its upcoming Secure Email and Messaging Solutions, PrivaTalk Messenger ("PTM"), the Company's Swiss hosted encrypted and private instant messaging application for all devices on web and mobile devices, equipped with privacy tools and anti-phishing technology.

With the exponential increase in recent Business Email Compromise ("BEC") attacks for business emails and the latest phishing campaign targeting Office 365, exploits brand names, published on the website threadpost.com on June 18 2020, the Company has received increased interest in its PTM solution. Additionally, recent data breaches in messaging applications and in particular in the WhatsApp application have created a certain urgency for businesses to protect their communications form cyber-attacks and identity theft via mobile devices.

The Company is already receiving interest in India as India is grappling with a surge in the number of cyber-attacks. Recently, the Company announced a distribution agreement in India and the demand has been swift. The projects revolve around healthcare and financial sectors for larger enterprises. The Company is also working with its other distributors in Sri Lanka as that country is coming out of confinement due to the COVID-19 pandemic.

Alain Ghiai, CEO of GlobeX Data said: "We are seeing an urgent need for cyber security and secure cloud and communications solutions, such as the ones we provide. Business is coming back in India and Sri Lanka, and we are in daily communications with our distributors. We expect to do better than we thought in the region, considering the huge economic impact COVID-19 has had in the South Asia region. India looks to be bigger than we though, as their cyber-attacks have increased by more than 35% from Q4 2019 to Q1 2020. Our new PTM solution is popular and simple to use, while it protects users' data and comes with our proprietary technologies, including anti-phishing technology. COVID-19 has put global businesses under pressure and has created an increased awareness for secure cloud business solutions such as GlobeX's. We believe that this trend will only continue moving forward, and India is no exception as we expect robust sales growth in the coming quarters for the region."

PrivaTalk Messenger or ("PTM"), is the Company's Swiss hosted secure communications suite, which includes encrypted messaging with self-destruct timer and the Company's encrypted email service called Custodia. Custodia is a secure email with proprietary SecureSend and SecureReply anti-phishing and privacy technology. SecureSend lets a user send an email to any other recipient in full privacy and security as the email never leaves Custodia's encrypted email servers based in Switzerland. The recipient can then click on the notification and reply in the same SecureSend manner, called SecureReply, without the recipient having to purchase PrivaTalk Messenger or Custodia. This process is revolutionary as no information is traveling on the open internet and the privacy and security of both the sender and recipient are guaranteed. A sender can also add a password protection, a limit on the reads by the recipient and a self-destruct timer for each email sent. This is also a guarantee to eliminate BEC attacks for businesses and email phishing attacks.

One of the many Privacy and security features of PrivaTalk Messenger is that the user does not register with their phone number, eliminated a huge loophole in security and privacy. Just recently, according to an article written by Lindsey O'Donnell and posted on the website threatpost.com on June 5 2020, it was disclosed that WhatsApp phone numbers and users were searchable on Google, creating a massive security and privacy breach. Earlier in the year, an article was written about a similar flaw affecting all businesses, NGOs, UN and non-profit organizations, where WhatsApp Group members were also compromised and searchable in a reverse engineering trick done on Google.

PrivaTalk Messenger eliminates many of the privacy and security risks by not only not requiring a phone number, which would divulge a user's phone device ID, but also by not social engineering a user's phone or computer contact list and infecting the contacts by default as well. PrivaTalk Messenger issues each user a username and a PTM number. The PTM number is the contact ID a user would disclose in order for other PTM users to be added. The service comes with a self-destruct timer and other features as well, including GlobeX's proprietary VirtualVaults and HeliX technologies with all data stored in Swiss hosted encrypted servers.

GlobeX's Data privacy solutions are all hosted in Switzerland, protecting users' data from any outside data intrusion requests. In Switzerland, the right to privacy is guaranteed in article 13 of the Swiss Federal Constitution. The Federal Act on Data Protection ("FADP") of 19 June 1992 (in force since 1993) has set up a strict protection of privacy by prohibiting virtually any processing of personal data which is not expressly authorized by the data subjects. The protection is subject to the authority of the Federal Data Protection and Information Commissioner.

Under Swiss federal law, it is a crime to publish information based on leaked "secret official discussions." In 2010 the Federal Supreme Court of Switzerland found that IP addresses are personal information and that under Swiss privacy laws they may not be used to track Internet usage without the knowledge of the individuals involved.

About GlobeX Data Ltd.
GlobeX Data Ltd. is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure data management and secure communications. The Company distributes a suite of secure cloud-based storage, disaster recovery, document management, encrypted e-mails, and secure communication tools. GlobeX Data Ltd. sells its products through its approved wholesalers and distributors, and telecommunications companies worldwide. GlobeX Data Ltd. serves consumers, businesses and governments worldwide.

On behalf of Management

GLOBEX DATA LTD.

Alain Ghiai
President and Chief Executive Officer
+1.416.644.8690
corporate@globexdatagroup.com

For more information please contact GlobeX Data at corporate@globexdatagroup.com or visit us at https://globexdatagroup.com.

For more information on DigitalSafe visit us at: https://digitalsafe.com.
For more information on PrivaTalk and PrivaTalk Messenger visit us at: https://privatalk.com.

Forward Looking Information
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ("forward-looking statements"). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "project" and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions "may" or "will" occur. These statements are only predictions. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guaranteeing future performance. GlobeX cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond GlobeX's control. Such factors include, among other things: risks and uncertainties relating to the future of the Company's business; the success of marketing and sales efforts of the Company; the projections prepared in house and projections delivered by channel partners; the Company's ability to complete the necessary software updates; increases in sales as a result of investments software development technology; consumer interest in the Products; future sales plans and strategies; reliance on large channel partners and expectations of renewals to ongoing agreements with these partners; anticipated events and trends; the economy and other future conditions; and other risks and uncertainties, including those described in GlobeX's prospectus dated May 8, 2019 filed with the Canadian Securities Administrators and available on www.sedar.com. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, GlobeX undertakes no obligation to publicly update or revise forward-looking information.

SOURCE: GlobeX Data Ltd.

ReleaseID: 594884

VANCOUVER, BC and LAS VEGAS, NV / ACCESSWIRE / June 23, 2020 / Ovation Science Inc. (CSE:OVAT) ("Ovation" or the "Company"), announces it has expanded distribution of its DermSafe® hand sanitizer lotion to Mexico. Ovation's new distributor, Grupo Venta International, S.A. de C.V. ("Grupo Venta"), with corporate offices in Guadalajara, Mexico, has made their first purchase of over 10,000 bottles of DermSafe, which they will begin distributing through-out Mexico. DermSafe® is a pharmaceutical-grade hand sanitizer lotion that uses chlorhexidine gluconate; an ingredient used worldwide in hospitals as it has a proven ability to kill germs. DermSafe has been developed with patented Invisicare® technology, which binds the product to the hands and resists wash-off and rub-off.

Grupo Venta, founded in 1990, is a company dedicated to supplying the highest quality, cutting-edge surgical equipment, supplies, cosmetic and wellness products through-out Mexico. They have three distinct business units. With its forty-six sales representatives across the country, they target various medical specialties including over 3,000 dermatologists, 1,900 surgeons and other medical specialists and hospitals. Secondly, they employ a B2B and B2C strategy which focuses on bringing post-surgical and dermatology products to be sold in doctors' offices as well as retail and on their online portal called "Top Care Store". Thirdly, Grupo Venta utilizes a retail and online strategy for wellness products marketed by department stores, pharmacies, and through various other online marketplaces in Mexico. This opportunity with Grupo Venta provides the Company with the ability to expand its sales efforts of DermSafe hand sanitizer through an established medical distributor with a robust distribution network.

"We are thrilled that Grupo Venta has proceeded very quickly with their desire to make DermSafe available through-out Mexico through their medical and consumer distribution channels. We knew they were excited to get onboard when over 80 sales representatives and staff participated in our virtual training. We were also impressed when they shortly after organized a physicians' virtual training for this week," said Terry Howlett, President of Ovation. "Doctors understand that alcohol hand sanitizers can have a devastating effect on your hands and that contact dermatitis caused by the alcohol can be very painful for people." He added, "Grupo Venta is well positioned in Mexico to sell DermSafe as they have an established distribution system to both medical professionals and consumers and they understand the need for a pharmaceutical-grade hand sanitizer like DermSafe."

"We are pleased to be working with Ovation Science and to be able to provide DermSafe hand sanitizer to help protect the citizens of Mexico during this devastating COVID-19 pandemic. Adding DermSafe to our current COVID-19 product offering is a great fit as we interact with physicians and consumers across our country with other medical, surgical and aesthetic / wellness products," said Ms. Gabriela González Alonso, Director General and C.E.O. of Grupo Venta. "As we have seen a surge of COVID-19 cases in Mexico recently, we are thankful that we can do our part by bringing high quality products such as DermSafe to the marketplace."

For information about Ovation Science products visit https://ovationscience.com/products/.

Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.

To learn more about Ovation Science, please visit:

About Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation's management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance that the Company's DermSafe product will be licensed or approved for sale in Mexico, and that if approval is obtained that it will result in sales. Although DermSafe has been tested against other envelope viruses there is no assurance that it will kill or be as effective against COVID-19. In addition there is no assurance the Company's level of sales will continue or will not be negatively impacted by increased competition and recovery from the coronavirus pandemic. Other examples of the assumptions underlying the forward-looking statements contained herein include, but are not limited to those related to: strategies, potential sales, distribution and manufacturing of the Company's product as well as its effectiveness against COVID-19, the Company's ability to receive regulatory approval outside of Canada. There are no guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.

Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact:

INVESTOR RELATIONS:

Sebastian Kunyz: ovat@kincommunications.com Phone: 604-684-6730 or Toll Free at 866-684-6730

FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:

Doreen McMorran: doreen@ovationscience.com Phone: 604-283-0903 ext. 4

SOURCE: Ovation Science Inc.

ReleaseID: 594819

NEW YORK, NY / ACCESSWIRE / June 23, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating KD033, an anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors. KD033 is a novel immunotherapy designed to stimulate innate and adaptive immune responses directed to the tumor microenvironment.

"We are pleased to initiate clinical development of KD033, which has demonstrated encouraging efficacy and durability in a variety of tumor types in preclinical models," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "By directing the anti-tumor activity of IL-15 to the tumor microenvironment, KD033 has the potential to stimulate patients' immune responses to fight cancer while avoiding systemic toxicities. This study initiation represents an important milestone for Kadmon and our platform of IL-15-containing fusion proteins. We look forward to providing further updates on this trial as they become available."

Recombinant IL-15 (rIL-15) is an immunostimulatory cytokine that has demonstrated clinical activity in the treatment of several cancers. rIL-15 expands key tumor-fighting cell types, including natural killer (NK), natural killer T (NKT) cells and memory T cells, without expanding immunosuppressive Treg cells, allowing for robust and durable anti-tumor responses. Clinical use of rIL-15 has been limited by its short half-life and narrow therapeutic window. To address these challenges, Kadmon has developed KD033, which is designed to direct IL-15 activity to the tumor microenvironment of PD-L1-expressing tumors and to achieve a greater therapeutic window. KD033 is designed to promote long-lasting efficacy while reducing systemic exposure of IL-15 to potentially increase safety and tolerability.

In preclinical studies, a single dose of KD033 demonstrated robust in vivo pharmacological activity and inhibited tumor growth across multiple syngeneic mouse models. KD033 also induced T-cell memory, resulting in mice that remained tumor-free following several tumor re-challenges. KD033 demonstrated significant tumor inhibition in animal models that are resistant to approved immunotherapies such as PD-L1, PD-1 or CTLA-4 antibodies.

About the KD033-101 Clinical Trial

KD033-101 is a Phase 1, open-label, dose-escalation and dose-expansion study investigating the safety and efficacy of KD033 in patients with metastatic or locally advanced solid tumors. The dose-escalation phase of the study will evaluate the pharmacokinetics and pharmacodynamics and identify the maximum tolerated dose (MTD) of KD033. The dose-expansion phase of the study will enroll approximately 15 patients who have progressed or are refractory to programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor therapy to assess safety, efficacy and determine the recommended Phase 2 dose (RP2D) of KD033.

About KD033

KD033 is a novel immunotherapy developed in-house and is fully owned by Kadmon. KD033 combines an anti-PD-L1 antibody with IL-15, a cytokine that expands key tumor-fighting cell types, including natural killer (NK), natural killer T (NKT) and memory T cells, to potentially induce durable responses and inhibit tumor growth. The anti-PD-L1 antibody directs IL-15 activity to the tumor microenvironment, limiting systemic exposure of IL-15 to potentially increase safety and tolerability. KD033 was well tolerated in GLP toxicology studies at clinically relevant doses. KD033 process development and manufacturing was completed through a successful collaboration with Wuxi Biologics and exhibited desired manufacturability and stability criteria.

KD033 is the most advanced candidate from Kadmon's IL-15 fusion protein platform. The Company is developing a portfolio of therapies combining IL-15 with select antibodies for the treatment of cancer.

About Kadmon

Kadmon is a biopharmaceutical company developing innovative products for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases as well as immuno-oncology.

Forward-Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the impact of COVID-19 on our ability to conduct our business or our clinical trials, (ii) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (iii) our ability to advance product candidates into, and successfully complete, clinical trials; (iv) our reliance on the success of our product candidates; (v) the timing or likelihood of regulatory filings and approvals, including an NDA regarding belumosudil (KD025); (vi) our ability to expand our sales and marketing capabilities; (vii) the commercialization of our product candidates, if approved; (viii) the pricing and reimbursement of our product candidates, if approved; (ix) the implementation of our business model, strategic plans for our business, product candidates and technology; (x) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (xi) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xii) costs associated with defending intellectual property infringement, product liability and other claims; (xiii) regulatory developments in the United States, Europe, China, Japan and other jurisdictions; (xiv) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xvi) our ability to maintain and establish collaborations or obtain additional grant funding; (xvii) the rate and degree of market acceptance of our product candidates; (xviii) developments relating to our competitors and our industry, including competing therapies; (xix) our ability to effectively manage our anticipated growth; (xx) our ability to attract and retain qualified employees and key personnel; (xxi) the use of proceeds from our recent public offerings; (xxii) the potential benefits of any of our product candidates being granted orphan drug designation; (xxiii) the future trading price of the shares of our common stock and impact of securities analysts' reports on these prices; and/or (xxiii) other risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including Kadmon's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact Information

Ellen Cavaleri
Investor Relations
646.490.2989
ellen.cavaleri@kadmon.com

SOURCE: Kadmon Holdings, Inc.

ReleaseID: 594820

Epsilogen to Host Key Opinion Leader Webinar on IgE Antibodies to Treat Cancer

Lead therapeutic candidate MOv18 IgE is the world's first IgE drug to enter clinical trials

Live webinar and conference call on Monday June 29th @ 11am ET / 4pm BST

LONDON, UK / ACCESSWIRE / June 23, 2020 / Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, announced today that it will host a Key Opinion Leader (KOL) webinar for the investment community on its IgE platform on Monday, June 29, 2020 at 11am ET (4pm BST).

Epsilogen's lead product candidate, MOv18 IgE, is in a Phase I clinical trial in folate receptor alpha positive cancer patients. This is the world's first IgE drug to enter clinical trials. Interim data show that MOv18 IgE has an acceptable safety profile and a preliminary efficacy signal was also seen. Epsilogen has also developed the IGEG™ platform of hybrid IgE/IgG antibodies which combine the functionality of IgE and IgG antibodies into a single molecule.

The webinar will feature presentations by KOLs Bristi Basu, MD, University of Cambridge, and James Spicer, MD, King's College London, who have together played a key role in advancing development of MOv18 IgE. Dr. Basu's presentation will include highlights of the interim data from the ongoing Phase 1 clinical study of MOv18 IgE in ovarian cancer that were presented at the recent AACR Virtual Annual Meeting I.

The Epsilogen management team, led by Tim Wilson PhD, will discuss the company's proprietary IgE technology platforms and will outline plans to further develop MOv18 IgE and other therapeutic candidates.

Drs. Basu and Spicer, as well as members of the Epsilogen management team, will be available for questions are the conclusion of the call.

Dial in & Webcast Information

Domestic: 877-705-6003
International: 201-493-6725
Conference ID: 13705401
Webcast: Click Here for Webcast

Bristi Basu, MD is a Cancer Research UK Consultant Medical Oncologist in Experimental Cancer Therapeutics at Cambridge University Hospitals NHS Trust (UK). She trained in Medicine at Oxford University before undertaking clinical specialty training in Medical Oncology at Cambridge. During this time, she completed a PhD in cancer cell biology and drug discovery at the University of Cambridge. She has worked with experimental cancer therapy agents in several early phase trials both at Addenbrooke's Hospital, Cambridge and at the Drug Development Unit, Royal Marsden Hospital, Surrey.

James Spicer, MD is the Professor of Experimental Cancer Medicine, King's College London, and Consultant in Medical Oncology, Guy's and St. Thomas' Hospitals London, UK. Dr Spicer is Professor of Experimental Cancer Medicine at King's College London, and Consultant in Medical Oncology at Guy's and St Thomas' Hospitals. He runs the King's Health Partners Cancer Early Phase Trials program. He is joint lead of the King's Experimental Cancer Medicine Center, funded by Cancer Research UK/National Institute for Health Research. Dr Spicer's interests include the care of patients with thoracic malignancies, including lung cancer and mesothelioma, and clinical trials in these diseases. His translational research focus is on novel treatment including immunotherapies. He is a member of CRUK's New Agents Committee and other UK national funding panels.

About Epsilogen Ltd

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.

The company has raised Series A finance from Epidarex Capital, ALSA Ventures and the UCL Technology Fund.

For more information, visit www.epsilogen.com.

CONTACT

Tim Wilson
Chief Executive Officer
Epsilogen Ltd
tim@epsilogen.com
+44 (0)20 3657 7612

U.S. Investor Contact
Hans Vitzthum
hans@lifesciadvisors.com
Phone: +1 (617) 535-7743

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Epsilogen Limited

ReleaseID: 594902

MONTRÉAL, QC / ACCESSWIRE / le 23 juin 2020 / Corporation Métaux Précieux du Québec (« QPM » ou la « Société ») (TSXV :CJC)(OTCQB:CJCFF)(FSE:YXEP) a le plaisir d'annoncer la reprise de ses travaux d'exploration sur son projet Sakami, détenu à 100 %, sur le territoire québécois d'Eeyou Istchee Baie-James. Les travaux incluent la réalisation de 7 000 m de forage au diamant sur le secteur de la découverte de La Pointe Extension, débutant au mois de juillet avec une foreuse. Les activités de forage peuvent être effectuées toute l'année (voir les communiqués de presse des 14 janvier, 21 avril et 18 juin 2020).

L'objectif est de prolonger la découverte de La Pointe Extension, qui consiste en plusieurs intersections importantes en forage, dont 1,15 g/t Au sur 80,1 mètres. Les sondages réalisés récemment sur la découverte de La Pointe Extension indiquent un système minéralisé aurifère et un potentiel d'exploration important à 2 km au sud-ouest du gîte de La Pointe. Les cibles de forage sont définies par des anomalies spatialement corrélées de polarisation provoquée (« PP ») et pédogéochimiques en or-arsenic ainsi que des indices aurifères en surface le long d'un axe minéralisé bien défini.

Les travaux durant le mois de juin comprennent :

un levé de PP pour prolonger les anomalies connues au sud-ouest;
la prise de données d'imagerie des parois de sondages choisis pour faciliter l'interprétation géologique; et
un levé bathymétrique près du rivage de la zone du gîte de La Pointe.

QPM a mis en place un protocole rigoureux pour assurer la protection de toutes les parties prenantes de la région et selon les directives de l'INSPQ et la CNESST dans le contexte de la pandémie COVID-19. Le protocole de la Société a été communiqué et revu par le Gouvernement de la Nation Crie. QPM reconnaît l'excellente coopération des autorités cries pour aider aux programmes d'exploration pendant cette période difficile. La Société a conclu son programme d'exploration d'hiver le 25 mars 2020 afin de respecter le décret du gouvernement du Québec en réponse à la pandémie de COVID-19.

Personnes qualifiées

Normand Champigny, ing., chef de la direction de la Société et Jean-Sébastien Lavallée, (OGQ # 773), géologue, vice-président exploration, administrateur et actionnaire de la Société, deux personnes qualifiées en vertu du Règlement 43-101 sur les normes de divulgation concernant les projets miniers, ont préparé et approuvé le contenu technique du présent communiqué.

À propos de Corporation Métaux Précieux du Québec

QPM est une société d'exploration aurifère avec de vastes terrains dans la région très prometteuse d'Eeyou Istchee Baie-James, au Québec, à proximité de la mine d'or Éléonore de Newmont Corporation. Le projet phare de QPM est le projet Sakami avec des teneurs significatives et des cibles bien définies prêtes à forer. L'objectif de QPM est d'avancer rapidement le projet à l'étape de l'estimation de ressources minérales.

Pour plus amples renseignements, communiquer avec :

Jean-François Meilleur
Président
Téléphone : 514 951-2730
Courriel : jfmeilleur@qpmcorp.ca

Normand Champigny
Chef de la direction
Téléphone : 514 979-4746
Courriel : nchampigny@qpmcorp.ca

La Bourse de croissance TSX et son fournisseur de services de réglementation
(au sens attribué à ce terme dans les politiques de la Bourse de croissance TSX)
n'assument aucune responsabilité quant à la pertinence ou à l'exactitude du présent communiqué.

LA SOURCE : Corporation Métaux Précieux du Québec

ReleaseID: 594800

NEW YORK, NY / ACCESSWIRE / June 23, 2020 / It's understandable when people have hesitations about something they do not entirely understand. The same is true when it involves going into business – no one would dare put their money on something they've only just heard about. Dropshipping expert, Jared Oks, is about to change people's perception about the unique e-commerce business model that made him rich.

A unique feature of dropshipping as a business is that it doesn't require a person to store inventory. It automatically spares the person from spending on expensive rental and storage costs. All that is involved in it is connecting with manufacturers, retailers, wholesalers, or suppliers and making their high-ticket products available in one's online store. A dropshipper sends the order and shipping details directly to the source of the item. The latter will take care of shipping the item to the client.

In dropshipping, the entrepreneur earns either through a percentage cut or the difference between the wholesaler price and the selling price. Jared strongly recommends that people should only go for products that sell for $500 and up. His team has sold items as high as $25,000. This made him realize that with the right packaging and connections, anything can be sold on a dependable e-commerce platform.

23-year-old, Oks, started contemplating the idea of starting a business while in college. He realized by then that he wasn't cut out to work 8 hours a day in a cubicle job. He understood that the only way he could achieve his dream lifestyle is to start his own business. His first business venture wasn't a success. Jared and his college roommate lost thousands and ended up broke and in debt.

Fortunately, someone believed in him enough to invest in his second attempt at developing his own business. Jared finally hit a gold mine. At present, he runs six stores, 4 of which are his own. Collectively, the stores earn nearly $1,000,000 each month in sales just two years from their establishment. His e-commerce business has allowed him to buy his real estate and start an impressive stock market portfolio. He knows that none of these would have happened if he decided to stay in school and wait to be hired after graduation.

To help aspiring businesses become successful at dropshipping, Jared launched an online community called Have More Than Money. The community offers one-on-one mentorship that paves the way for success and fulfillment in life. Through this, Jared hopes to simplify dropshipping as a business to members so that they, too, can enjoy what he is now reaping as a young businessman.

An e-book titled, "How to Have More Than Money," is available for free to anyone who signs up in the site. Jared hopes to empower more people and make them confident enough to try out the same business model that made him a successful person. Dropshipping may not be for everybody, but surely, someone out there is more than willing to take a risk to create a better life.

Jared's achievement can be anyone's success with the right amount of determination and hard work. At the end of the day, it's not the business model that makes someone rich, but the unseen personal values that drive a person to work even when he doesn't feel like it.

To know more about Jared Oks and Dropshipping, you may contact him at (917) 800-0478 or email him at Jared@havemorethanmoney.com

SOURCE: Authority Titans

ReleaseID: 595030

TORONTO, ON / ACCESSWIRE / June 23, 2020 / AEX Gold Inc. ("AEX" or the "Corporation") (TSXV:AEX) is pleased to announce that it has received confirmation from the Greenlandic Covid Commission that its plan to mobilize personnel to its properties in South Greenland amid the Covid19 environment met all of the requirements of the authorities.

Since the start of the crisis in March 2020, AEX has engaged diligently with various specialists from the medical services, occupational health and safety, insurances and legal sectors as well as with the Greenlandic authorities to implement Standard Operating Procedures ("SOPs") which aim to minimize the risks of Covid19 contamination for all stakeholders, and in line with industry best practice.

The Corporation will continue to have a collaborative and proactive approach with the Greenlandic government to monitor the evolution of the crisis and has developed contingency plans to adjust for any new development in a flexible and efficient manner without materially impacting the Corporation's future plans or its assessment of the economic viability of its projects.

AEX intends to submit its Field Application documents to the Greenlandic Authorities in early July for authorization ahead of mobilizing personnel, which is expected to occur around the end of July

Eldur Olafsson, CEO of AEX Gold, comments:

"We are encouraged by the authorisation we have received from the Greenlandic Covid Commission and we look forward to welcoming back our employees and resuming the development of Nalunaq and carrying out exploration activities. We continue to work closely with the Greenland government to ensure we are following all of the guidelines in place to protect our local communities and personnel."

Stock Option Awards

The Corporation also announces that it has granted incentive stock options ("Options") to directors, officers and consultants of AEX to acquire an aggregate of 2,195,000 common shares at $0.70 per share, with an expiry date of December 31, 2026.

END

Contact Information

George Fowlie, Director and CFO
1-416-587-9801
gf@aexgold.com

Eldur Olafsson, Director and CEO
+354 665 2003
eo@aexgold.com

Camarco (Financial PR)

Gordon Poole / Nick Hennis
+44 (0) 20 3757 4980

About AEX

AEX's principal business objectives are the identification, acquisition, exploration and development of gold properties in Greenland. The Corporation's principal asset is a 100% interest in the Nalunaq Project, an advanced exploration stage property with an exploitation license including the previously operating Nalunaq gold mine. AEX is incorporated under the Canada Business Corporations Act and wholly owns Nalunaq A/S, incorporated under the Greenland Public Companies Act.

Forward-Looking Information

This press release contains forward-looking information within the meaning of applicable securities legislation, which reflects the Corporation's current expectations regarding future events and the future growth of the Corporation's business. In this press release there is forward-looking information based on a number of assumptions and subject to a number of risks and uncertainties, many of which are beyond the Corporation's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to the factors discussed under "Risk Factors" in the Final Prospectus available under the Corporation's profile on SEDAR at www.sedar.com. Any forward-looking information included in this press release is based only on information currently available to the Corporation and speaks only as of the date on which it is made. Except as required by applicable securities laws, the Corporation assumes no obligation to update or revise any forward-looking information to reflect new circumstances or events. No securities regulatory authority has either approved or disapproved of the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: AEX Gold Inc.

ReleaseID: 594740